Evidence map›Paper›PMID 37474630›Full record

ArticleScientific reports2023

An immunomodulating peptide to counteract solar radiation-induced immunosuppression and DNA damage.

Michael Agrez, Mark Stephen Rybchyn, Warusavithana Gunawardena Manori De Silva, Rebecca Sara Mason, Christopher Chandler, Terrence J Piva, Kristofer Thurecht, Nicholas Fletcher, Feifei Liu, Gayathri Subramaniam and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 3 countries.

Michael AgrezInterK Peptide Therapeutics Limited, Sydney, NSW, Australia. michael.agrez@interk.com.au.
Mark Stephen RybchynSchool of Medical Sciences and Bosch Institute, University of Sydney, Sydney, Australia.
Warusavithana Gunawardena Manori De SilvaSchool of Medical Sciences and Bosch Institute, University of Sydney, Sydney, Australia.
Rebecca Sara MasonSchool of Medical Sciences and Bosch Institute, University of Sydney, Sydney, Australia.
Christopher ChandlerAuspep Pty Limited, Melbourne, Australia.
Terrence J PivaHealth and Biomedical Sciences, RMIT University, Melbourne, Australia.
Kristofer ThurechtCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Nicholas FletcherCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Feifei LiuCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Gayathri SubramaniamCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Christopher B HowardCentre for Advanced Imaging, University of Queensland, Brisbane, Australia.
Benjamin BlythPeter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology at the University of Melbourne, Melbourne, Australia.
Stephen ParkerInterK Peptide Therapeutics Limited, Sydney, NSW, Australia.
Darryl TurnerConcept Life Sciences Limited, Edinburgh, Scotland.
Justyna RzepeckaConcept Life Sciences Limited, Edinburgh, Scotland.
Gavin KnoxConcept Life Sciences Limited, Edinburgh, Scotland.
Anastasia NikaConcept Life Sciences Limited, Edinburgh, Scotland.
Andrew HallConcept Life Sciences Limited, Edinburgh, Scotland.
Hayley GoodingConcept Life Sciences Limited, Edinburgh, Scotland.
Laura GallagherConcept Life Sciences Limited, Edinburgh, Scotland.
Concept Life Sciences (United Kingdom) · GBNational Imaging Facility · AUThe University of Sydney · AUARC Centre of Excellence in Advanced Molecular Imaging · AURMIT University · AUTCI Peptide Therapeutics (United States) · USThe University of Melbourne · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ultraviolet radiation (UVR) induces immunosuppression and DNA damage, both of which contribute to the rising global incidence of skin cancer including melanoma. Nucleotide excision repair, which is activated upon UVR-induced DNA damage, is linked to expression of interleukin-12 (IL-12) which serves to limit immunosuppression and augment the DNA repair process. Herein, we report an immunomodulating peptide, designated IK14800, that not only elicits secretion of IL-12, interleukin-2 (IL-2) and interferon-gamma (IFN-γ) but also reduces DNA damage in the skin following exposure to UVR. Combined with re-invigoration of exhausted CD4+ T cells, inhibition of UVR-induced MMP-1 release and suppression of B16F10 melanoma metastases, IK14800 offers an opportunity to gain further insight into mechanisms underlying the development and progression of skin cancers.

Indexed as

MelanomaSkin NeoplasmsDNA DamageDNA RepairHumansImmunosuppression TherapyInterleukin-12Ultraviolet RaysInterleukin-12

Identifiers

PMID37474630
PMCPMC10359417
OpenAlexW4384922748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.